NovoCure (NVCR) Change in Receivables (2017 - 2023)
NovoCure's Change in Receivables history spans 7 years, with the latest figure at -$2.6 million for Q3 2023.
- On a quarterly basis, Change in Receivables rose 77.07% to -$2.6 million in Q3 2023 year-over-year; TTM through Sep 2023 was -$20.3 million, a 165.14% decrease, with the full-year FY2022 number at -$2.5 million, up 51.67% from a year prior.
- Change in Receivables hit -$2.6 million in Q3 2023 for NovoCure, up from -$6.9 million in the prior quarter.
- Over the last five years, Change in Receivables for NVCR hit a ceiling of $19.7 million in Q1 2020 and a floor of -$14.5 million in Q1 2023.
- Historically, Change in Receivables has averaged $1.8 million across 5 years, with a median of $2.0 million in 2019.
- Biggest five-year swings in Change in Receivables: surged 868.47% in 2020 and later crashed 409.23% in 2022.
- Tracing NVCR's Change in Receivables over 5 years: stood at $19.5 million in 2019, then tumbled by 116.44% to -$3.2 million in 2020, then surged by 57.93% to -$1.3 million in 2021, then skyrocketed by 379.96% to $3.8 million in 2022, then tumbled by 170.06% to -$2.6 million in 2023.
- Business Quant data shows Change in Receivables for NVCR at -$2.6 million in Q3 2023, -$6.9 million in Q2 2023, and -$14.5 million in Q1 2023.